Aspiriant LLC Has $374,000 Position in Zoetis Inc. (NYSE:ZTS)

Aspiriant LLC grew its stake in Zoetis Inc. (NYSE:ZTS) by 26.0% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,213 shares of the company’s stock after purchasing an additional 456 shares during the period. Aspiriant LLC’s holdings in Zoetis were worth $374,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in the business. GoalVest Advisory LLC boosted its position in Zoetis by 29.1% during the 1st quarter. GoalVest Advisory LLC now owns 679 shares of the company’s stock worth $115,000 after buying an additional 153 shares during the period. Future Financial Wealth Managment LLC acquired a new stake in Zoetis during the 1st quarter worth approximately $51,000. IAM Advisory LLC boosted its position in Zoetis by 2.6% during the 1st quarter. IAM Advisory LLC now owns 9,296 shares of the company’s stock worth $1,573,000 after buying an additional 235 shares during the period. Security National Bank raised its holdings in Zoetis by 1.3% during the 1st quarter. Security National Bank now owns 47,467 shares of the company’s stock worth $8,032,000 after purchasing an additional 609 shares during the last quarter. Finally, Sarasin & Partners LLP raised its holdings in Zoetis by 69.1% during the 1st quarter. Sarasin & Partners LLP now owns 348,691 shares of the company’s stock worth $59,002,000 after purchasing an additional 142,496 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Stock Performance

Shares of ZTS stock opened at $176.51 on Friday. The firm has a market capitalization of $80.54 billion, a PE ratio of 34.01, a price-to-earnings-growth ratio of 2.65 and a beta of 0.88. The firm has a fifty day simple moving average of $167.68 and a two-hundred day simple moving average of $178.94. The company has a current ratio of 3.33, a quick ratio of 1.94 and a debt-to-equity ratio of 1.30. Zoetis Inc. has a 12 month low of $144.80 and a 12 month high of $201.92.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Thursday, May 2nd. The company reported $1.38 EPS for the quarter, beating analysts’ consensus estimates of $1.34 by $0.04. The business had revenue of $2.19 billion during the quarter, compared to analyst estimates of $2.14 billion. Zoetis had a net margin of 27.38% and a return on equity of 50.34%. Zoetis’s quarterly revenue was up 9.5% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.31 EPS. Analysts forecast that Zoetis Inc. will post 5.76 EPS for the current fiscal year.

Zoetis Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, September 4th. Shareholders of record on Thursday, July 18th will be paid a dividend of $0.432 per share. The ex-dividend date of this dividend is Thursday, July 18th. This represents a $1.73 dividend on an annualized basis and a yield of 0.98%. Zoetis’s dividend payout ratio (DPR) is presently 33.33%.

Analyst Ratings Changes

ZTS has been the subject of several analyst reports. Piper Sandler restated an “overweight” rating and set a $195.00 price target (down previously from $220.00) on shares of Zoetis in a report on Tuesday, April 16th. Barclays lowered their price target on shares of Zoetis from $260.00 to $230.00 and set an “overweight” rating for the company in a report on Tuesday, April 23rd. Stifel Nicolaus lowered their price target on shares of Zoetis from $195.00 to $180.00 and set a “buy” rating for the company in a report on Tuesday, April 30th. HSBC lowered their price target on shares of Zoetis from $230.00 to $225.00 and set a “buy” rating for the company in a report on Wednesday, May 8th. Finally, The Goldman Sachs Group lowered their price target on shares of Zoetis from $223.00 to $196.00 and set a “buy” rating for the company in a report on Monday, May 6th. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $211.75.

Insiders Place Their Bets

In other Zoetis news, EVP Roxanne Lagano sold 923 shares of Zoetis stock in a transaction on Thursday, April 18th. The shares were sold at an average price of $151.17, for a total transaction of $139,529.91. Following the transaction, the executive vice president now directly owns 14,800 shares of the company’s stock, valued at approximately $2,237,316. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.16% of the company’s stock.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.